28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Extreme sleepiness and insomnia not only influence physical health, they also have a significant impact on mental health, such as by causing depression, which has a prevalence of 18% to 21% among young adults aged 16 to 24 in the United Kingdom. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Subjective cognitive decline is a symptom that may appear in the early stages of Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI), an identified prodromal stage of Alzheimer's Disease (AD), often evades detection in the early stages of the condition, when existing diagnostic methods are employed in the clinical setting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The positive results pave the way for the deployment of the system to a nonsupervised environment, thus representing a potential efficacious and ecological solution to support clinicians in the identification of early signs of cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Due to the lack of pharmacological treatment for dementia, timely detection of subjects at risk can be of seminal importance for preemptive rehabilitation interventions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Smartphones and wearables could provide beneficial and pervasive support and monitoring for rehabilitation among people with dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Relying on procedural memory is a promising approach for interventions that address the cognitive difficulties found in semantic dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The digitalized complex figure test evaluated copying performance quantitatively and further elucidated the patients' ongoing process during copying. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The One Card Learning Test (OCL80) from the Cogstate Brief Battery-a digital cognitive test used both in-person and remotely in clinical trials and in healthcare contexts to inform health decisions-has shown high sensitivity to changes in memory in early Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The AD group performed significantly lower on the associative learning (p = 0.01) and associative memory assessments (p = 0.002), than the HC and AR groups. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a progressive, multifactorial, chronic, neurodegenerative disease with high prevalence and limited therapeutic options, making it a global health crisis. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Herein, combined with a pervasive smartphone installed with a color recognition app, dual-responsive CDs@Eu/GMP ICPs were designed as a red-to-blue paper-based colorimetric sensor for the point-of-use analysis of cerebral acetylcholinesterase (AChE) upon Cd2+ exposure. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In regards to policy-making decisions and resource allocation, the success of making technology more accessible to the marginalized older population should not be measured solely on the outcome of avoiding acute care services; its benefits should rather be assessed with functional health as the focus of intervention, including measures of psychophysical well-being and life satisfaction.9 Higher-end immersive technologies could be installed as a private expense in a patient's room; they could also be made available in common recreational areas within a leisure and/or fitness room, provided by the LTC facility through support of government subsidies and incentives aimed at promoting health of its aging population. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hearing loss affects close to 1.3 billion people and is a growing global health concern as the fourth leading contributor to years lived with disability. 1 The global economic cost associated with hearing loss is estimated at 750 billion United States dollars (US$) annually.2 However, hearing loss has limited public health support, especially in low-and middle-income countries, where incidence is high and resources often scarce and unequally distributed.
Evidence: low
Full summary, score breakdown and related studies → Original source
The system uses a collected dataset of 1928 records, taken from 11 HD patients and 11 healthy persons in Lithuania, to gather statistics about examinations and presents the results as medical evaluation with prediction on the state of health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The current neuropsychiatric nosological categories underlie pragmatic treatment choice, regulation and clinical research but does not encompass biological rationale. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Touchscreen devices (e.g. tablets) can be supportive for people with mild dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Intraindividual decline in cognitive performance can be detected in otherwise healthy, community-dwelling, older persons, and this may deserve further study as a potential indicator of early Alzheimer's disease pathology. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with ERP, MRI, or neuropsychological tests alone, the VR-DOT could provide additional predictive information in a low-cost, computerized, and noninvasive way. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent statistics released by Alzheimer's Disease International has highlighted how prevalent dementia will become in the next couple of years. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study showed that, while it has not been previously an area of focus, individuals with DS can complete a computerised cognitive training programme. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In a cohort of 75 patients who completed Moneta's program (average age 73 ± 10, average MoCA score 20 ± 5), 59% had MCI and 33% had dementia. 5 key findings →
Participants: 75 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research investigating treatments and interventions for cognitive decline and Alzheimer's disease (AD) suffer due to difficulties in accurately identifying individuals at risk of AD in the pre-symptomatic stages of the disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
All participants had significant increases in independent response frequencies, level of personal satisfaction, and heart rates during program sessions as opposed to baseline or control sessions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
During baseline, the mean frequency of correct target responses was virtually zero. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →